Qianjiang Yongan Pharmaceutical Co., Ltd.

Equities

002365

CNE100000LZ9

Pharmaceuticals

End-of-day quote Shenzhen S.E. 06:00:00 2024-04-29 pm EDT 5-day change 1st Jan Change
8.24 CNY +10.01% Intraday chart for Qianjiang Yongan Pharmaceutical Co., Ltd. +22.99% -15.75%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Qianjiang Yongan Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Qianjiang Yongan Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Qianjiang Yongan Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023 CI
Qianjiang Yongan Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Qianjiang Yongan Pharma Patents Purification Method For Taurine Mother Liquor in Europe, Indonesia MT
Qianjiang Yongan Pharmaceutical Co., Ltd Approves Cash Dividend for the Year 2022, Payable on July 5, 2023 CI
Yongan Pharma Registers New Health Food Products MT
Qianjiang Yongan Pharma to Buy 6.5% Stake in Local Chemical Producer For 30 Million Yuan MT
Huanggang Yongan Pharmaceutical Co., Ltd. announced that it expects to receive CNY 30 million in funding from Qianjiang Yongan Pharmaceutical Co., Ltd. CI
Qianjiang Yongan Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Qianjiang Yongan Pharmaceutical Co., Ltd. Proposes Final Dividend for the Year 2022 CI
Qianjiang Yongan Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Yongan Pharma Unit Gets Food Registration Certificate for Ginseng Tablets MT
Qianjiang Yongan Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022 CI
Qianjiang Yongan Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022 CI
Qianjiang Yongan Pharma Patents Taurine, Salt Preparation in Japan MT
Qianjiang Yongan Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022 CI
Qianjiang Yongan Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2021 CI
Qianjiang Yongan Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2021 CI
Qianjiang Yongan Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2021 CI
Qianjiang Yongan Pharmaceutical Co., Ltd. Announces Final Cash Dividend for 2020, Payable on July 9, 2021 CI
Yongan Pharmaceutical Approves Final Cash Dividend for the Year 2020 CI
Wuhan Low-dimensional Materials Research Institute Co., Ltd. announced that it has received CNY 10 million in funding from Qianjiang Yongan Pharmaceutical Co., Ltd. CI
Qianjiang Yongan Pharmaceutical Co., Ltd. completed the acquisition of 35% stake in Wuhan Low-dimensional Materials Research Institute Co., Ltd. from Li Ganghui and Wuhan Xinlian Huida Technology Investment Partnership (Limited Partnership). CI
Wuhan Low-dimensional Materials Research Institute Co., Ltd. announced that it expects to receive CNY 10 million in funding from Qianjiang Yongan Pharmaceutical Co., Ltd. CI
Chart Qianjiang Yongan Pharmaceutical Co., Ltd.
More charts
Qianjiang Yongan Pharmaceutical Co., Ltd. is a China-based company principally engaged in the manufacture and sales of taurine products. The Company operates through three main segments. The Taurine Products segment is mainly engaged in the research, development, manufacture and sales of taurine products, as well as the manufacture and sales of ethylene oxide. The Food Supplement segment is mainly involved in the research, development, manufacture and sales of dietary supplement, as well as the import and sales of overseas dietary supplement. The Health Field segment is mainly involved in the equity or industrial investment in health-related field.
More about the company

Annual profits - Rate of surprise

  1. Stock Market
  2. Equities
  3. 002365 Stock
  4. News Qianjiang Yongan Pharmaceutical Co., Ltd.
  5. Qianjiang Yongan Pharma Patents Purification Method For Taurine Mother Liquor in Europe, Indonesia